Navigation Links
Aurigene's Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones

BRIDGEWATER, New Jersey, April 22, 2013 /PRNewswire/ --

Aurigene and Endo entered into collaboration in 2009, for multiple integrated drug discovery programs in the areas of Inflammation and Oncology.


In one of the programs, a novel selective dual kinase inhibitor, targeting both the antigen receptor signalling and cytokine signalling pathways involved in immune regulation for inflammatory disorders, has been chosen for IND-enabling toxicology studies by Endo.

In a second program, targeting two different growth factor signalling pathways in oncology, a novel class of compounds is being developed, and is in the late lead optimization phase. This program has the potential to deliver multiple candidates for clinical development, targeting several unmet needs for solid tumors.

"We are pleased to be working with a really accomplished and ambitious team at Endo, and these collaborative efforts have enabled us to aim at delivering unique clinical candidates with a profile that is potentially significantly differentiated in the clinic", remarked Dr. Murali Ramachandra , Sr Vice President, Pre-clinical Biology, Aurigene.

"The programs being carried out at Aurigene are an integral part of Endo's strategy to discover novel drug candidates that improve patient outcomes. We are excited about the possibility for the current programs to be important additions to our development pipeline" commented Dr. Sandeep Gupta , Senior Vice President of Drug Discovery and Early Development at Endo.

About Aurigene

Aurigene is a Biotech focussed on building a robust pipeline of small molecule and peptide therapeutics in the exciting areas of Cancer Metabolism, Epigenetics and the TH17 pathway. Aurigene's most advanced programs in its pipeline include several compounds expected to be in clinical development over the next few months, for oncology, inflammation and anti-infective indications. These are (a) PD-1 peptide therapeutics for oncology and antibacterial indications; (b) A novel protease inhibitor for Osteo Arthritis (DMOAD) and pain alleviation; (c) A differentiated FabI inhibitor with potential for IV/ oral switch, for MRSA.

In addition, Aurigene works with Pharma companies on early stage collaborations in integrated discovery partnerships. Aurigene, with over 500 scientists in its Indian and Malaysian laboratories, has collaborated with 6 of the top 10 pharma companies, in addition to partnerships with mid-sized pharma companies and biotechs in the US and Europe.

For more information on Aurigene's collaboration business model, and its pipeline, please visit the company's website at

Media Contacts:
Mark Ravera , Head of Business Development, USA
Rajshree KT +91-40-4465-7777
Head Strategic Alliances, India

SOURCE Aurigene
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Israel’s Top BioEnergy Researchers Are Arriving Today at Oak Ridge National Laboratory For Deliberations to Establish U.S.-Israel Collaboration
2. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
3. Bayer CropScience Promotes Bee Health Awareness and Collaboration
4. TrueVision® 3D Surgical and i-Optics Announce Collaboration to Integrate Diagnostics and Computer-Guidance in Cataract Surgery
5. Top BioEnergy Researchers and Innovators Arriving Next Week to Foster U.S.-Israel Collaboration
6. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
7. Smith & Nephew releases new Modular Rail System in collaboration with Dr. Dror Paley
8. Starpharma and Makhteshim Agan in Priostar Agrochemical Collaboration
9. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
10. AMRI and Codexis Announce Technology Collaboration
11. Japanese Universities Offered Access to SPIE Digital Library in Collaboration with JUSTICE
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):